CN109106948B - Foot-and-mouth disease antigen protective agent and application thereof - Google Patents
Foot-and-mouth disease antigen protective agent and application thereofDownload PDFInfo
- Publication number
- CN109106948B CN109106948BCN201811096573.3ACN201811096573ACN109106948BCN 109106948 BCN109106948 BCN 109106948BCN 201811096573 ACN201811096573 ACN 201811096573ACN 109106948 BCN109106948 BCN 109106948B
- Authority
- CN
- China
- Prior art keywords
- foot
- mouth disease
- protective agent
- reducing agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Translated fromChinese
Description
Technical Field
The invention relates to the field of vaccine production, in particular to a foot-and-mouth disease antigen protective agent and application thereof.
Background
Foot and Mouth Disease (FMD) is a virulent infectious Disease caused by Foot and Mouth Disease Virus (FMDV), and is characterized in that the skins of the Mouth, feet and other parts of infected artiodactyl animals can generate blisters, so that partial animals can die, and huge economic loss is caused. The foot-and-mouth disease is one of animal infectious diseases which are legally reported by the animal health Organization (OIE) in the world, because the foot-and-mouth disease has strong pathogenic variability (7 serotypes exist, cross protection cannot be carried out between types), strong infectivity, high transmission speed and wide damage area, and can cause huge economic loss and social influence. Foot and mouth disease is classified as a type of epidemic disease in our country. This fully shows the degree of attention to foot-and-mouth disease at home and abroad.
The foot-and-mouth disease virus vaccine is invented in 1926 by Valley, Carr é et al, France, and the inactivated vaccine (O type) is prepared by inoculating a hamster kidney cell line (BHK-21) with the foot-and-mouth disease virus, culturing, inactivating harvested culture by using diethylene imine (BEI), and mixing and emulsifying by adding a mineral oil adjuvant. The appearance was a milky white or light pink emulsion.
With the progress of scientific technology, the quality requirement of the vaccine is higher and higher. At present, foot-and-mouth disease vaccines have unstable immune protective force, and antibodies cannot be detected or the level of generated antibodies is low after immunization, or the immune period is short, the main reason is that the effectiveimmune components 146S in the foot-and-mouth disease vaccines are not fully protected, the existing vaccine preparation processes are mostly traditional methods, and no proper protective agent is used for ensuring the integrity and immunogenicity of antigens. This current situation adversely affects the control of foot and mouth disease epidemic and the development of the foot and mouth disease vaccine industry in our country.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The first purpose of the invention is to provide a foot-and-mouth disease antigen protective agent, which can protect the integrity of the foot-and-mouth disease antigen, inhibit the degradation of theactive ingredient 146S, ensure the immunogenicity of the foot-and-mouth disease antigen and is suitable for long-term storage of the foot-and-mouth disease antigen.
The second purpose of the invention is to provide a composition containing a foot-and-mouth disease antigen, the composition comprises the foot-and-mouth disease antigen and the protective agent, the foot-and-mouth disease antigen can be stably stored for a long time, and the protective agent component does not interfere with the measurement result of the Lowry method on total nitrogen and does not influence the evaluation of the purity of the vaccine, the national standard and the GMP standard.
The third purpose of the invention is to provide a method for preparing the foot-and-mouth disease vaccine, which has reasonable design, simple and convenient operation, safe and high-efficiency use.
In order to achieve the above purpose of the present invention, the following technical solutions are adopted:
a foot-and-mouth disease antigen protective agent is composed of the following substances in percentage by mass and volume: 5 to 20 percent of carbohydrate reducing agent, 0.08 to 1.1 per mill of protein disulfide bond reducing agent, 1.5 to 4.5 percent of amino acid cosolvent and 0.5 to 3 percent of protein protective agent;
the sugar reducing agent comprises one or more of xylitol, lactose and fructose;
the protein disulfide bond reducing agent comprises DTT and/or TCEP.
A composition containing foot-and-mouth disease antigen, which comprises the protective agent.
A method for preparing foot-and-mouth disease vaccine, mixing the above-mentioned foot-and-mouth disease antigen with the above-mentioned protective agent.
Compared with the prior art, the invention has the beneficial effects that: the invention provides a foot-and-mouth disease protective agent which is safe and efficient to use, can protect the antigen of the foot-and-mouth disease, protect the integrity of the antigen, inhibit 146S degradation and ensure the immunogenicity of the antigen. And the good protection of the protective agent is verified through a 37-degree aging resistance experiment and a 45-degree accelerated aging experiment. Has important significance for the control of foot-and-mouth disease epidemic situation and the development of foot-and-mouth disease vaccine industry in China.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 is a liquid phase diagram of foot and mouth disease antigen aging at 37 ℃ for 14 days in various protective agents in one embodiment of the invention;
FIG. 2 is a liquid phase diagram of the accelerated aging of foot and mouth disease antigen at 45 ℃ for 9h in various protective agents according to one embodiment of the present invention;
FIG. 3 is an electron microscope result graph of foot-and-mouth disease antigen with protective agent added after accelerated aging at 45 ℃ for 9h in one embodiment of the invention;
FIG. 4 is an electron microscope result of foot-and-mouth disease antigen without protective agent added after accelerated aging at 45 ℃ for 9h in one embodiment of the present invention.
Detailed Description
A foot-and-mouth disease antigen protective agent is composed of the following substances in percentage by mass and volume: 5 to 20 percent of carbohydrate reducing agent, 0.08 to 1.1 per mill of protein disulfide bond reducing agent, 1.5 to 4.5 percent of amino acid cosolvent and 0.5 to 3 percent of protein protective agent;
the sugar reducing agent comprises one or more of xylitol, lactose and fructose;
the protein disulfide bond reducing agent comprises DTT and/or TCEP.
DTT is Dithiothreitol, British name DL-Dithiothreitol, molecular weight 154.25. In some embodiments, the mass volume percentage of the DTT in the protective agent is 0.03% to 0.38%.
TCEP is Tris (2-carboxyethyl) phosphine, known in England as Tris (2-carboxyethyl) phosphine, molecular weight 286.7. In some embodiments, the TCEP is present in the protectant in an amount from 0.05 to 0.72% by volume.
The total nitrogen content needs to be measured in the vaccine quality detection for evaluating the purity of the antigen. Such as higher total nitrogen for the protective agent, or interference of the agent with the total nitrogen determination, will likely affect the objective assessment of vaccine quality. The components of the protective agent do not interfere with the determination result of total nitrogen, and do not influence the evaluation of the purity of the vaccine, the national standard and the GMP standard.
The foot-and-mouth disease antigen protective agent provided by the invention is reasonable in design and is very suitable for long-acting protection of the foot-and-mouth disease antigen.
The sugar reducing agent is preferably a polyhydroxy sugar, and is more preferably one or more of xylitol, lactose and fructose. The saccharide can be used as a reducing agent, has a co-dissolving effect, and can form a protective shell on the surface of a protein molecule to be protected to play a stabilizing role. The polyhydroxy sugar can form a hydration film on the surface of the virus capsid protein to be protected, and plays a role in stabilizing, and the protective capability of different sugars to antigens is different.
In some embodiments, the protective agent may further comprise the following substances in percentage by mass and volume: 9 to 15 percent of carbohydrate reducing agent, 0.16 to 0.5 per mill of protein disulfide bond reducing agent, 2 to 4 percent of amino acid cosolvent and 0.5 to 2 percent of protein protective agent. In some embodiments, the amino acid-based co-solvent comprises one or more of cysteine, glycine, arginine.
In some embodiments, the proteinaceous protective agent comprises albumin and/or serum protein.
Protein-based protectants can maintain the stability of the protein to be protected. The protein protective agents which can be selected without antigens are different, and corresponding experiments and detection are needed according to different antigens.
In some embodiments, the protective agent may further comprise the following substances in percentage by mass and volume: the composition comprises 18% of a carbohydrate reducing agent (6% of xylitol, 6% of lactose and 6% of fructose), 0.7% of a protein disulfide bond reducing agent (0.4% of DTT and 0.3% of TCEP), 4% of an amino acid cosolvent (1% of cysteine, 2% of glycine and 1% of arginine) and 1% of a protein protective agent (0.8% of albumin and 0.2% of serum protein); 5% of carbohydrate reducing agent (xylitol 2%, lactose 2%, fructose 1%), 1.1% of protein disulfide bond reducing agent (DTT 0.5% o, TCEP 0.6% o), 4.5% of amino acid cosolvent (cysteine 2%, glycine 1.5%, arginine 1%), 1.5% of protein protective agent (albumin 0.5%, serum protein 1%); 20% of carbohydrate reducing agent (12% of xylitol, 8% of lactose), 0.08% of protein disulfide bond reducing agent (0.03% of DTT, 0.05% of TCEP), 1.5% of amino acid cosolvent (0.5% of cysteine, 1.0% of glycine) and 2.5% of protein protective agent (1.2% of albumin and 1.3% of serum protein); 9% of a carbohydrate reducing agent (4% of xylitol and 5% of fructose), 0.16% of a protein disulfide bond reducing agent (0.16% of DTT), 2% of an amino acid cosolvent (1.2% of glycine and 0.8% of arginine) and 3% of a protein protective agent (3% of serum protein); 12% of carbohydrate reducing agent (lactose 8%, fructose 4%), 0.5% of protein disulfide bond reducing agent (TCEP 0.5%), 4% of amino acid cosolvent (cysteine 1.8%, arginine 2.2%), and 2% of protein protective agent (albumin 2%); 15% of carbohydrate reducing agent (xylitol 4%, lactose 5%, fructose 6%), 0.25% of protein disulfide bond reducing agent (DTT 0.12% o, TCEP 0.13% o), 3% of amino acid cosolvent (cysteine 1%, glycine 1%, arginine 1%), 0.5% of protein protective agent (albumin 0.3%, serum protein 0.2%) and the like.
In some embodiments, the composition of the protectant further includes an inorganic equilibrium salt; preferably, the inorganic equilibrium salt comprises: 60 to 100mM HEPES, 70 to 100mM EDTA, 20 to 40mM KCl, 10 to 20mM MgCl2One or more of (a).
In some embodiments, the concentration of the HEPES may also be 70mM, 80mM, 90mM, 95mM, etc.; the concentration of EDTA may also be 75mM, 80mM, 90mM, 95mM, etc.; the concentration of KCl may be 25mM, 30mM, 35mM, etc.; MgCl2The concentration of (b) may be 12mM, 15mM, 18mM, etc.; the above ingredients resulted in substantially consistent results over their respective concentration ranges.
In some embodiments, the composition of the protective agent further comprises 0.5 to 1.0mM urea.
The urea can enhance the ionic strength and increase the charge number of the urea, thereby being beneficial to long-term storage. In some embodiments, the concentration of urea may also be 0.6mM, 0.8mM, 0.9mM, etc. (results are essentially consistent within this range).
In some embodiments, the pH of the protectant is 7.2 to 7.9.
In some embodiments, the pH may also be 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, etc. (results are essentially consistent within this range).
Another aspect of the present invention is to provide a composition containing a foot-and-mouth disease antigen, which includes the above-mentioned protective agent.
In some embodiments, the foot and mouth disease antigen comprises an inactivated antigen and/or an inactivated antigen.
In some embodiments, the concentration of the active ingredient of the foot-and-mouth disease antigen in the composition is 1 to 200. mu.g/mL.
Preferably, the foot-and-mouth disease antigen solution is replaced by using an ultrafiltration concentration tube, so that the antigen is stored in the protective agent and can be stored for at least 18 months at 4 ℃.
Another aspect of the present invention is to provide a method for preparing a vaccine for foot-and-mouth disease, which comprises mixing the above-mentioned antigen for foot-and-mouth disease with the above-mentioned protective agent, adjusting pH, and sterilizing.
In some embodiments, the vaccine further comprises an adjuvant, which is added during the mixing.
Preferably, the adjuvant comprises ISA 206 or ISA201VG oil adjuvant.
In some embodiments, the aftosa antigen protective agent can be applied to effective antigen preservation in hog cholera, blue ear, pseudorabies whole virus inactivated vaccine and subunit vaccine.
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
The chemical reagents involved in the present application are shown in table 1.
TABLE 1 chemical reagents used
| Manufacturer of the product | Purity of | |
| HEPES | sigma | Analytical purity |
| KCl | sigma | Analytical purity |
| Reduced matter | sigma | Analytical purity |
| EDTA | sigma | Analytical purity |
| MgCl2 | sigma | Analytical purity |
| NaOH | Beijing chemical industry | Analytical purity |
Example 1
60mM HEPES, 100mM EDTA, 20mM KCl, 20mM MgCl2Preparing 10X mother liquor from 0.5mM urea, weighing 20g of carbohydrate reducing agent (9 g of xylitol and 11g of fructose), 0.008g of protein disulfide bond reducing agent (DTT 0.003g and TCEP 0.005g), 4.5g of amino acid cosolvent (cysteine 2g, glycine 1g and arginine 1.5g) and 0.5g of protein protective agent (albumin and/or serum protein), dissolving the components in water, fixing the volume to 100mL, adjusting the pH to 7.2, sterilizing and filtering by using a 0.22um filter membrane, and storing at 4 ℃.
Example 2
100mM HEPES, 70mM EDTA, 40mM KCl, 10mM MgCl2Preparing 10X mother liquor from 1.0mM urea, weighing 5g of carbohydrate reducing agent (lactose 2g and fructose 3g), 0.11g of protein disulfide bond reducing agent (TCEP 0.11g), 1.5g of amino acid cosolvent (cysteine 1g and glycine 0.5g) and 3g of protein protective agent (albumin 1g and serum protein 2g), adding water to dissolve the components, fixing the volume to 100mL, adjusting the pH to 7.3, sterilizing and filtering by using a 0.22um filter membrane, and storing at 4 ℃.
Example 3
80mM HEPES, 90mM EDTA, 30mM KCl, 15mM MgCl2Preparing 10X mother liquor from 0.7mM urea, weighing 10g of carbohydrate reducing agent (6 g of xylitol and 4g of lactose), 0.04g of protein disulfide bond reducing agent (DTT 0.04g), 2g of amino acid cosolvent (glycine 0.8g and arginine 1.2g) and 2g of protein protective agent (albumin 2g), adding water to dissolve the components, fixing the volume to 100mL, adjusting the pH value to 7.4, sterilizing and filtering by using a 0.22um filter membrane, and storing at 4 ℃.
Example 4
70mM HEPES, 80mM EDTA, 25mM KCl, 18mM MgCl2Preparing 10X mother liquor by 0.8mM urea, weighing 15g of carbohydrate reducing agent (6 g of xylitol, 4g of lactose and 5g of fructose), 0.02g of protein disulfide bond reducing agent (0.01 g of DTT and 0.01g of TCEP), 4g of amino acid cosolvent (2 g of cysteine and 2g of arginine) and 1g of protein protective agent (1 g of serum protein), adding water to dissolve the components, fixing the volume to 100mL, adjusting the pH to 7.9, sterilizing and filtering by using a 0.22um filter membrane, and storing at 4 ℃.
Example 5
75mM HEPES, 90mM EDTA, 32mM KCl, 13mM MgCl2Preparing 10X mother liquor by 0.6mM urea, weighing 18g of carbohydrate reducing agent (5 g of xylitol, 8g of lactose and 5g of fructose), 0.06g of protein disulfide bond reducing agent (0.03 g of DTT and 0.03g of TCEP), 3g of amino acid cosolvent (1 g of cysteine, 1g of glycine and 1g of arginine) and 1.5g of protein protective agent (0.7 g of albumin and 0.8g of serum protein), dissolving the components in water, fixing the volume to 100mL, adjusting the pH to 7.7, sterilizing by using a 0.22um filter membrane, filtering, and storing at 4 ℃.
Experimental example 1
The aging experiment at 37 ℃ proves that I.
Setting comparative examples, the comparative examples are set on the basis of example 5, specifically:
comparative example 1: replacing the reducing agent with sucrose of the same mass;
comparative example 2: the proteinaceous protective agent was replaced with peptone of the same mass.
The buffer system of the antigen solution was replaced with the protectant for the foreign plant, the protectant for this product (example 5) and the buffer system in the comparative example by using a GE 100kD ultrafiltration concentrator tube, aseptically filtered, and then subpackaged in an EP tube, aged at 37 ℃ and subjected to an aging test with theaftosa 146S antigen without the protectant as a control for 3 days, 7 days, 11 days and 14 days. The content of the foot-and-mouth disease virus 146S is determined by Waters liquid phase detection (see Table 2), and the protection rate is calculated according to the detection result (see Table 3).
TABLE 237 ℃ aging 146S measurement results
TABLE 337 ℃ comparison of aging protection
As can be seen from tables 2 and 3, the protective rate of the protective agent in the embodiment can reach 75.71% after the protective agent is placed at 37 ℃ for 14 days, and 146S of the antigen without the protective agent is only preserved by 5.23%, so that the protective agent has obvious effect and is obviously superior to other manufacturers. Moreover, it can be seen from the comparative example that the protective effect is remarkably reduced after the corresponding components are replaced by sucrose which is the saccharide reducing agent or peptone which is the protein protective agent.
And (5) ageing experiment verification at 37 ℃ is two.
As can be seen from the 146S liquid phase detection spectrum in FIG. 1, the protective rate of the product after aging at 37 ℃ for 14 days is 75.71%, while the protective rate of the control group without the protective agent is only 5.23% against theantigen 146S, and the 146S loss is large.
Experimental example 2
The accelerated aging test at 45 ℃ proves that I.
In order to further verify the protection effect, the invention improves the thermal cracking resistance temperature, and adopts an aging experiment of samples accelerated at 45 ℃, wherein the sampling time is 3h, 6h and 9 h. The concentration of 146S of the foot-and-mouth disease virus was measured (see Table 4), and the protective rate was calculated from the results of the measurement (see Table 5).
TABLE 445 ℃ accelerated ageing 146S measurement results
TABLE 545 ℃ accelerated aging protection Rate comparison
As can be seen from tables 4 and 5, the protective agent in the example has a protective rate of 56.44% after accelerated aging at 45 ℃ for 9h, and has a significant protective effect compared with the antigen without the protective agent and other protective agents. Compared with antigen without protective agent, the protective effect is obvious and is obviously better than that of other manufacturers. Moreover, it can be seen from the comparative example that the protective effect is remarkably reduced after the corresponding components are replaced by sucrose which is the saccharide reducing agent or peptone which is the protein protective agent.
And (5) verifying by an accelerated aging experiment at 45 ℃.
As can be seen from the 146S liquid phase detection spectrum in FIG. 2, after 9 hours of 45 ℃ accelerated aging test, the 146S residual content of the protective agent is equivalent to 56.4 percent of the original protective agent at most, and the highest protective agent of other manufacturers is only 16.9 percent.
Experimental example 3
The effect of the protective agent on the toxicity value.
To investigate the effect of protective agents on the titer of antigens, we performed antigens using the BHK21 cell lineThe virus titer of the TCID50 virus titer is 10-6、10-7、10-8In each titer, 8 wells were assayed in parallel, antigen without protective agent was set as a control, and three replicates were performed to verify the degree of effect.
TABLE 6 TCID50 test results
| TCID50 | Other manufacturers 1 | Protective agent for product | Original antigen |
| Parallel experiment 1 | 10-7.25/0.1ml | 10-7.43/0.1ml | 10-7.33/0.1ml |
| Parallel experiment 2 | 10-7.25/0.1ml | 10-7.33/0.1ml | 10-7.25/0.1ml |
| Parallel experiment 3 | 10-7.33/0.1ml | 10-7.49/0.1ml | 10-7.33/0.1ml |
As can be seen from Table 6, the control mean value was 10-7.300.1ml, the protective agent is 10-7.400.1ml, the toxicity of the protective agent is slightly higher but the difference is not obvious, and the protective agent has certain protective effect on the original toxicity.
Experimental example 4
Viral particle completeness detection.
After accelerated aging at 45 ℃ for 9h, the virus particles added with the protective agent and without the protective agent are observed by using an electron microscope. The results are shown in FIGS. 3 and 4. It can be seen that after the protective agent is added and aged for 9h at 45 ℃, the whole virus particles still exist in the visual field observed by an electron microscope, but the particles are completely cracked after the antigen without the protective agent is aged for 9h at 45 ℃. The aging resistance effect of the protective agent is proved to be remarkable.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (9)
1. The composition containing the foot-and-mouth disease antigen is characterized by comprising a protective agent, wherein the protective agent consists of the following substances in percentage by mass and volume: 5-20% of a carbohydrate reducing agent, 0.08-1.1% of a protein disulfide bond reducing agent, 1.5-4.5% of an amino acid cosolvent and 0.5-3% of a protein protective agent;
the sugar reducing agent consists of xylitol, lactose and fructose;
the protein disulfide bond reducing agent consists of DTT and TCEP;
the protein protective agent consists of albumin and serum protein;
the amino acid cosolvent consists of cysteine, glycine and arginine.
2. The composition of claim 1, wherein the protectant composition further comprises an inorganic counter salt.
3. The composition of claim 2, wherein the inorganic counter-salt comprises: 60 to 100mM HEPES, 70 to 100mM EDTA, 20 to 40mM KCl, 10 to 20mM MgCl2One or more of (a).
4. The composition of claim 1, wherein the protectant further comprises 0.5 to 1.0mM urea.
5. The composition of claim 1, wherein the pH of the protecting agent is 7.2 to 7.9.
6. The composition of claim 1, wherein said foot and mouth disease antigen comprises inactivated and/or non-inactivated antigens.
7. The composition according to claim 6, wherein the concentration of the active ingredient of the foot-and-mouth disease antigen in the composition is 1 to 200. mu.g/mL.
8. A method for preparing a foot-and-mouth disease vaccine, which comprises adjusting the pH of the composition according to any one of claims 1 to 7, and sterilizing the composition.
9. The method according to claim 8, characterized in that the sterilization is filtration through a sterile 0.22 μm filter membrane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811096573.3ACN109106948B (en) | 2018-09-19 | 2018-09-19 | Foot-and-mouth disease antigen protective agent and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811096573.3ACN109106948B (en) | 2018-09-19 | 2018-09-19 | Foot-and-mouth disease antigen protective agent and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109106948A CN109106948A (en) | 2019-01-01 |
| CN109106948Btrue CN109106948B (en) | 2022-03-29 |
Family
ID=64859483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811096573.3AActiveCN109106948B (en) | 2018-09-19 | 2018-09-19 | Foot-and-mouth disease antigen protective agent and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109106948B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114904006B (en)* | 2022-05-27 | 2023-10-17 | 中农威特生物科技股份有限公司 | Foot-and-mouth disease antigen thermal stability protective agent and preparation method and application thereof |
| CN119055764A (en)* | 2024-08-29 | 2024-12-03 | 洛阳赛奥生物工程技术有限公司 | Antigen protective agent and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1413733A (en)* | 2002-06-19 | 2003-04-30 | 中国农业科学院兰州兽医研究所 | Foot-and-mouth disease virus antigen preservation technology |
| CN104548085A (en)* | 2014-12-09 | 2015-04-29 | 吕宏亮 | Aftosa totivirus particle vaccine composition as well as preparation method and application thereof |
| CN108504638A (en)* | 2017-02-28 | 2018-09-07 | 中国科学院过程工程研究所 | A kind of aftosa inactivation of viruses antigen purification or the method for storage |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005123120A1 (en)* | 2004-06-16 | 2005-12-29 | Smart Drug Systems Inc. | Sustained release vaccine composition |
| US20130309273A1 (en)* | 2012-05-17 | 2013-11-21 | Kimberly Hassett | Thermostable Vaccine Compositions and Methods of Preparing Same |
| HK1206636A1 (en)* | 2012-04-02 | 2016-01-15 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
- 2018
- 2018-09-19CNCN201811096573.3Apatent/CN109106948B/enactiveActive
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1413733A (en)* | 2002-06-19 | 2003-04-30 | 中国农业科学院兰州兽医研究所 | Foot-and-mouth disease virus antigen preservation technology |
| CN104548085A (en)* | 2014-12-09 | 2015-04-29 | 吕宏亮 | Aftosa totivirus particle vaccine composition as well as preparation method and application thereof |
| CN108504638A (en)* | 2017-02-28 | 2018-09-07 | 中国科学院过程工程研究所 | A kind of aftosa inactivation of viruses antigen purification or the method for storage |
Non-Patent Citations (1)
| Title |
|---|
| 口蹄疫疫苗保存技术研究;李正丰;《中国优秀硕士学位论文全文数据库 农业科技辑》;20100615(第6期);第一章第1.5小节和第三章* |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109106948A (en) | 2019-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11207397B2 (en) | Virus purification | |
| Sakoonwatanyoo et al. | Growth and production of the dengue virus in C6/36 cells and identification of a laminin-binding protein as a candidate serotype 3 and 4 receptor protein | |
| ES2731337T3 (en) | High performance quantification and characterization of viruses and their products | |
| NO320958B1 (en) | Stabilizer, stabilized attenuated vaccine and method of preparing such a vaccine. | |
| WO2000023104A1 (en) | Freeze-dried hepatitis a attenuated live vaccine and its stabilizer | |
| ES2689150T3 (en) | Methods for preventing aggregation of viral components | |
| CN109106948B (en) | Foot-and-mouth disease antigen protective agent and application thereof | |
| US20080193478A1 (en) | Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus | |
| JPWO2009082002A1 (en) | Method for producing Japanese encephalitis vaccine that can be stably stored for a long period of time and use of the vaccine | |
| CN101730544B (en) | Adaptation of pitman moore strain of rabies virus to primary chick embryo fibroblast cell cultures | |
| CN105797164A (en) | Heat-resisting protective agent for TGEV and PEDV bigeminy freeze-drying live vaccine and preparing method and application of heat-resisting protective agent | |
| KR102544928B1 (en) | Composition for improving stability of antigen for animal vaccine or diagnosis comprising amino acid as effective component and uses thereof | |
| KR102623114B1 (en) | Method for Enhancing Purity of Foot-and-mouth Disease Vaccine Antigens | |
| RU2682876C1 (en) | Inactivated emulsion vaccine for o-type aphthous fever | |
| CN117004581B (en) | Application of ginsenoside Rb2 in inactivating virus | |
| CN109701012A (en) | A kind of vaccine adjuvant and its application and porcine reproductive and respiratory syndrome vaccine | |
| Saadh et al. | Whole-organism vaccine (attenuated and killed vaccines) | |
| CN104353068A (en) | Large-scale production method of rabies vaccines by using human diploid cells | |
| Selvaraj et al. | Formulation, Efficacy and Immunogenicity Studies of a Liquid State Rabies Vaccine with Magnesium Chloride as Stabilizer | |
| WO2024029469A1 (en) | Method for manufacturing inactivated sars-cov-2 vaccine, inactivated sars-cov-2 vaccine, method for purifying sars-cov-2 or inactivated sars-cov-2, and sars-cov-2 antigen composition or inactivated sars-cov-2 antigen composition | |
| JP2025501555A (en) | Stabilized liquid vaccine of live virus | |
| Hsue | Studies on the Multiplication of Japanese Encephalitis Virus I. Factors Influencing Plaque Formation of Japanese Encephalitis Virus | |
| Sanders | Development of novel inactivated poliovirus vaccines: Breaking away from convention | |
| EP3615006A1 (en) | Antigenic thermostable polio vaccines&related methods | |
| HK1223845B (en) | Methods for the prevention of aggregation of viral components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | Effective date of registration:20220130 Address after:215000 station 6-013, 6 / F, No. 88, modern Avenue, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu (cluster registration) Applicant after:Tiankang Pharmaceutical (Suzhou) Co.,Ltd. Address before:830000 No. 528 Changchun South Road, Urumqi high tech Industrial Development Zone, Xinjiang Uygur Autonomous Region Applicant before:TECON BIOLOGICAL Co.,Ltd. | |
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | Effective date of registration:20230506 Address after:830000 Room 201, Building 1, No. 46 Satellite Road, Phase II, Urumqi Economic Development Zone (Toutunhe District), Xinjiang Uygur Autonomous Region Patentee after:Tiankang biopharmaceutical Co.,Ltd. Address before:215000 station 6-013, 6 / F, No. 88, modern Avenue, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu (cluster registration) Patentee before:Tiankang Pharmaceutical (Suzhou) Co.,Ltd. | |
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | Denomination of invention:A foot-and-mouth disease antigen protector and its application Granted publication date:20220329 Pledgee:China Merchants Bank Co.,Ltd. Urumqi Branch Pledgor:Tiankang biopharmaceutical Co.,Ltd. Registration number:Y2025980029941 | |
| PE01 | Entry into force of the registration of the contract for pledge of patent right |